Antigens
Peripheral T-Cell Lymphoma Following CD19-Targeted Chimeric Antigen Receptor T Cell Therapy
A new study from Kumamoto University School of Medicine in Japan has shed light on the rare occurrence of peripheral T-cell lymphoma following CD19-targeted chimeric antigen receptor T cell therapy. Researchers investigated a case of a 66-year-old male patient who developed peripheral T-cell lymphoma eight months after receiving CD19-directed CAR